Phreesia, Inc. (NYSE:PHR) General Counsel Allison C. Hoffman Sells 3,495 Shares of Stock

Phreesia, Inc. (NYSE:PHR) General Counsel Allison C. Hoffman sold 3,495 shares of the firm’s stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $24.88, for a total transaction of $86,955.60. Following the transaction, the general counsel now directly owns 116,296 shares in the company, valued at $2,893,444.48. This trade represents a 2.92 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Phreesia Stock Down 0.7 %

PHR stock opened at $23.84 on Friday. The stock has a market capitalization of $1.39 billion, a PE ratio of -16.22 and a beta of 0.98. Phreesia, Inc. has a 52 week low of $17.07 and a 52 week high of $29.16. The company has a quick ratio of 1.77, a current ratio of 1.74 and a debt-to-equity ratio of 0.04. The firm has a 50 day moving average of $20.73 and a 200 day moving average of $21.91.

Phreesia (NYSE:PHR) last announced its quarterly earnings data on Monday, December 9th. The company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. The firm had revenue of $106.80 million for the quarter, compared to analyst estimates of $106.33 million. During the same period in the previous year, the company earned ($0.58) earnings per share. The business’s quarterly revenue was up 16.6% compared to the same quarter last year. Sell-side analysts forecast that Phreesia, Inc. will post -1.16 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on PHR. DA Davidson reiterated a “buy” rating and set a $32.00 price objective on shares of Phreesia in a research note on Thursday, September 5th. Royal Bank of Canada restated a “sector perform” rating and set a $23.00 price objective on shares of Phreesia in a research note on Friday, September 27th. Robert W. Baird cut their target price on Phreesia from $34.00 to $30.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 11th. JMP Securities reiterated a “market outperform” rating and issued a $30.00 target price on shares of Phreesia in a report on Tuesday, December 10th. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $34.00 price target on shares of Phreesia in a report on Thursday, September 5th. One investment analyst has rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $29.33.

Institutional Trading of Phreesia

Several large investors have recently added to or reduced their stakes in the company. Franklin Resources Inc. lifted its holdings in shares of Phreesia by 3.0% during the third quarter. Franklin Resources Inc. now owns 1,497,631 shares of the company’s stock worth $31,495,000 after purchasing an additional 42,973 shares during the period. Geode Capital Management LLC increased its holdings in Phreesia by 4.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,245,797 shares of the company’s stock worth $28,397,000 after buying an additional 55,934 shares during the period. M&T Bank Corp raised its position in Phreesia by 4.6% during the 3rd quarter. M&T Bank Corp now owns 35,127 shares of the company’s stock worth $801,000 after buying an additional 1,535 shares during the last quarter. Barclays PLC lifted its stake in Phreesia by 83.6% during the 3rd quarter. Barclays PLC now owns 94,929 shares of the company’s stock valued at $2,163,000 after acquiring an additional 43,225 shares during the period. Finally, XTX Topco Ltd purchased a new stake in shares of Phreesia in the 3rd quarter valued at $247,000. Hedge funds and other institutional investors own 92.10% of the company’s stock.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.